Nirvana Life Sciences Announces Health Canada Approval for Vancouver Facility Construction

VANCOUVER, BC, June 28, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV), a Western Canada-based life sciences company focused on developing products for the prevention of chronic pain and addiction-free relapses, is pleased to announce that Health Canada has granted Nirvana approval to build its research and development center in Vancouver, Canada.

Health from Canada The Office of Controlled Substances and Licensing Division has reviewed Nirvana’s proposed floor plan and design and has concluded that the Level 9 GMP secure facility should be constructed Vancouver meets the Physical Security Requirements Directive if built as proposed. Health Canada has advised the company that construction can begin at Vancouver location. Once construction is complete, the company will notify Health Canada and schedule an inspection to confirm that the completed construction complies with the guideline in order to be an Authorized Authorized Dealer.

Nirvana engaged Stratus Designs Ltd. to design and implement the control systems necessary to meet Health Canada’s stringent security requirements. The Stratus team has the experience and skills to complete the construction of the facility in a way that maximizes efficiency and meets GACP and GMP standards. Once completed, the Authorized Dealer License will give Nirvana the ability to import, export, test, research and develop, and sell controlled substances to qualified investigators and other authorized dealers. Nirvana has also already purchased $800,000 state-of-the-art laboratory equipment to be deployed in the facility after final inspection and approval by Health Canada.

Mr. Michael McCuneNirvana’s Vice President of Operations said, “This is what we expected, build approval is a critical milestone on our roadmap to becoming a fully licensed Authorized Dealer. We have the utmost confidence in Stratus Designs Ltd. to see this project through to completion and final approval, as they have a proven track record in building facilities for the pharmaceutical, nutraceutical and cannabis production sectors.”

About Nirvana Life Sciences Inc.

Nirvana Life Sciences Inc. was founded with a simple goal of researching and developing non-addictive pain management and relapse prevention products that can deliver healthier outcomes for patients who live with chronic pain and/or have struggled with addiction. Nirvana believes the use of naturally occurring psychedelics in new formulations promises to provide non-addictive solutions that are effective in managing pain and addiction. Nirvana’s team of leading researchers from around the world will develop therapies that have the potential to free millions of people from addiction and save society billions of dollars each year.

Forward-looking statements

This press release contains certain forward-looking statements and information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws, including, without limitation, statements regarding the Company’s future investments. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (general and specific) that contribute to the possibility that future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release and the assumptions on which such forward-looking statements are based are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on any forward-looking statements included herein, as there can be no assurance that the plans, intentions or expectations on which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved, which may cause actual performance and results of the Company in future periods differ materially from any estimate or projection of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any of the forward-looking statements included, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

SOURCENirvana Life Sciences Inc.

Quote

View original content: http://www.newswire.ca/en/releases/archive/June2022/28/c0476.html

About Stephen Ewing

Check Also

Framework and Toolkit for Infection Prevention and Control in Outbreak Preparedness, Preparedness and Response at the Health Care Facility Level

Insight Infectious disease outbreaks and epidemics are increasing in frequency, scale and impact. Healthcare facilities …